MAGEA3 and cancer: In a Phase II trial, postoperative MAGE-A3+ NSCLC patients (n=182) receiving MAGE-A3 antigen-specific cancer immunotherapy (ASCI) exhibited significantly reduced recurrence rates (30.6% vs 43.3% placebo) at primary analysis (190).